查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2125105

全球胃癌治療市場規模、佔有率、趨勢和成長分析報告（2026-2034）

Global Gastric Cancer Drugs Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 215 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球胃癌治療市場預計將從2025年的53.9億美元成長至2034年的128.6億美元，2026年至2034年的複合年成長率（CAGR）為10.14%。隨著製藥公司和醫療系統尋求更有效的胃癌和胃食道癌治療方案，該市場正在不斷擴張。治療方案包括化療、標靶治療、免疫療法和其他專科療法，取決於腫瘤的特徵和患者的需求。世界衛生組織（WHO）指出，胃癌仍然是全球癌症負擔沉重的疾病之一，對有效診斷和治療的需求持續存在。對分子層面特徵的深入了解也推動了針對特定患者群體的標靶治療的研發。因此，腫瘤學研究的進展為製藥公司開發更精準、更有效的治療策略創造了機會。

胃癌治療市場正受到生物標記檢測、標靶治療和免疫療法進展的影響。研究人員正不斷識別有助於判斷患者是否能從特定治療中獲益的分子特徵。因此，伴隨診斷和基因組檢測在治療方案選擇中變得日益重要。製藥公司也正在研究免疫療法、標靶治療和傳統療法的聯合應用，以期在疾病的不同階段改善治療效果。由於胃癌具有高度的生物學異質性，需要針對腫瘤生物學特徵差異和每位患者個體特徵制定相應的治療方法，因此臨床研究仍然至關重要。

未來前景光明，這得益於腫瘤學研究與開發的持續推進以及個人化治療策略的不斷發展。新的生物標記有望擴大標靶治療和免疫療法的適用範圍，而聯合治療則有望改善治療效果。此外，分子檢測的普及將使治療選擇更加精準，即使在醫療體系低度開發的地區也能如此。對於那些能夠滿足未被滿足的醫療需求並展現顯著臨床效益的製藥公司而言，預計將迎來龐大的商機。隨著研究人員對胃癌生物學特徵的深入了解，市場將繼續朝著生物標記主導療法、聯合治療以及日益個人化的治療方案發展。

我們的報告經過精心撰寫，旨在提供涵蓋廣泛行業和市場的全面且切實可行的洞察。每份報告都包含幾個關鍵組成部分，旨在幫助您全面了解市場環境：

市場概覽：本節對市場進行了清晰的說明，包括關鍵定義、分類以及當前行業格局的概述。

市場動態：對影響市場成長的主要促進因素、阻礙因素、機會和挑戰進行詳細評估。這包括技術發展、法律規範和不斷變化的行業趨勢等因素。

市場區隔分析：本部分依據產品類型、應用、最終使用者和地區，將市場系統性地分類為若干關鍵細分市場。本部分揭示了每個細分市場的表現、成長潛力和市場貢獻。

競爭格局：我們對主要市場參與企業進行了詳細評估，包括其市場定位、產品系列、策略舉措和財務表現。這有助於深入了解競爭趨勢和主要參與者所採取的策略。

市場預測：本部分提供基於數據的市場規模和成長模式預測，預測期為指定時期。它綜合考慮了歷史趨勢、當前市場狀況和定量分析，以識別預期的未來趨勢。

區域分析：透過全面檢驗主要地理區域的市場表現，並識別高成長領域和區域趨勢，我們可以更深入地了解每個區域的市場機會。

新趨勢與新機會：識別關鍵市場趨勢、技術進步和新興投資機會。本部分重點在於潛在成長領域和未來產業趨勢。

客製化選項：我們提供靈活的報告客製化服務，以滿足您的特定需求。這包括額外的細分、國家/地區分析、競爭對手分析、客製化資料點或針對特定細分市場的洞察，從而更有效地支援您的策略決策。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章：全球胃癌治療市場：依類型分類

  • 市場分析、洞察與預測
  • Imatinib（口服製劑、注射製劑、聯合治療）
  • 曲妥珠單抗（單藥治療、與化療聯合治療、曲妥珠單抗生物相似藥）
  • 其他類型（化療藥物、分子標靶療法、免疫療法、支持性治療藥物）

第5章：全球胃癌治療市場：依給藥途徑分類

  • 市場分析、洞察與預測
  • 口服
  • 腸外

第6章 全球胃癌治療市場：依最終用戶分類

  • 市場分析、洞察與預測
  • 醫院
  • 診所
  • 癌症專科醫療中心

第7章 全球胃癌治療市場：依地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第8章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第9章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • Arlak Biotech
    • Astellas Pharma Inc
    • AstraZeneca Plc
    • BeiGene
    • Biocad
    • Biocon
    • Bristol-Myers Squibb
    • CARsgen Therapeutics
    • Celon Pharma
    • Celltrion Inc
    • CStone Pharma
    • Daiichi Sankyo
    • Eli Lilly And Company
    • Eurofarma Laboratorios SA
    • F. Hoffmann-La Roche
    • Gilead Sciences
    • GlaxoSmithKline Plc
    • Jiangsu HengRui Medicine
    • Johnson & Johnson
    • JW Therapeutics
    • Merck & Co. Inc
    • Mylan Laboratories
    • Novartis Oncology
    • PV Pharma Healthcare
    • Pfizer Inc
    • Sandoz AG（Novartis）
    • Sanofi
    • Takeda Pharmaceuticals
    • Teva Pharmaceutical Industries Ltd
    • TUTEUR/Pierre Fabre Group
簡介目錄
Product Code: VMR112111253

The global gastric cancer drugs market size is expected to reach USD 12.86 Billion in 2034 from USD 5.39 Billion in 2025, growing at a CAGR of 10.14% during 2026-2034.This market is developing as pharmaceutical companies and healthcare systems seek improved treatment options for gastric and gastroesophageal cancers. Treatment approaches can include chemotherapy, targeted therapies, immunotherapy, and other specialized interventions depending on tumor characteristics and patient needs. According to the World Health Organization, stomach cancer remains an important global cancer burden, creating continued demand for effective diagnosis and treatment. Increasing understanding of molecular characteristics is also supporting the development of therapies designed for specific patient groups. Advances in oncology research are therefore creating opportunities for pharmaceutical companies developing more precise and effective treatment strategies.

The gastric cancer drugs market is being influenced by progress in biomarker testing, targeted therapies, and immune-based treatments. Researchers are increasingly identifying molecular characteristics that can help determine whether patients may benefit from particular therapies. Companion diagnostics and genomic testing are consequently becoming more relevant to treatment selection. Pharmaceutical companies are also investigating combinations of immunotherapies, targeted agents, and conventional treatments to improve outcomes across different disease stages. Clinical research remains important because gastric cancer is biologically diverse, requiring treatment approaches that can address differences in tumor biology and individual patient characteristics.

Future prospects are supported by continued oncology research and the development of personalized treatment strategies. New biomarkers could expand the number of patients eligible for targeted or immune-based therapies, while combination approaches may improve treatment effectiveness. Greater access to molecular testing could also support more precise treatment selection in developing healthcare systems. Drug developers that demonstrate meaningful clinical benefits while addressing unmet treatment needs are likely to find significant opportunities. The market should continue evolving toward biomarker-driven therapies, combination regimens, and increasingly individualized approaches as researchers deepen their understanding of gastric cancer biology.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Type

  • Imatinib (Oral Formulations, Injectable Formulations, Combination Therapies)
  • Trastuzumab (Monotherapy, Combination Therapy with Chemotherapy, Biosimilars of Trastuzumab)
  • Other Types (Chemotherapy Agents, Targeted Therapy Agents, Immunotherapy Agents, Supportive Care Medications)

By Route of Administration

  • Oral
  • Parenteral

By End User

  • Hospitals
  • Clinics
  • Cancer Specialty Centers

COMPANIES PROFILED

  • Arlak Biotech, Astellas Pharma Inc., AstraZeneca plc, BeiGene, Biocad, Biocon, Bristol-Myers Squibb, CARsgen Therapeutics, Celon Pharma, Celltrion Inc., CStone Pharma, Daiichi Sankyo, Eli Lilly and Company, Eurofarma Laboratorios S.A., F. Hoffmann-La Roche, Gilead Sciences, GlaxoSmithKline plc, Jiangsu HengRui Medicine, Johnson & Johnson, JW Therapeutics, Merck & Co. Inc., Mylan Laboratories, Novartis Oncology, PV Pharma Healthcare, Pfizer Inc., Sandoz AG (Novartis), Sanofi, Takeda Pharmaceuticals, Teva Pharmaceutical Industries Ltd., TUTEUR / Pierre Fabre Group

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL GASTRIC CANCER DRUGS MARKET: BY TYPE 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Type
  • 4.2. Imatinib (Oral Formulations, Injectable Formulations, Combination Therapies) Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Trastuzumab (Monotherapy, Combination Therapy with Chemotherapy, Biosimilars of Trastuzumab) Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Other Types (Chemotherapy Agents, Targeted Therapy Agents, Immunotherapy Agents, Supportive Care Medications) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL GASTRIC CANCER DRUGS MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Route Of Administration
  • 5.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Parenteral Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL GASTRIC CANCER DRUGS MARKET: BY END USER 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast End User
  • 6.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.4. Cancer Specialty Centers Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL GASTRIC CANCER DRUGS MARKET: BY REGION 2022-2034 (USD MN)

  • 7.1. Regional Outlook
  • 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.2.1 By Type
    • 7.2.2 By Route Of Administration
    • 7.2.3 By End User
    • 7.2.4 United States
    • 7.2.5 Canada
    • 7.2.6 Mexico
  • 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.3.1 By Type
    • 7.3.2 By Route Of Administration
    • 7.3.3 By End User
    • 7.3.4 United Kingdom
    • 7.3.5 France
    • 7.3.6 Germany
    • 7.3.7 Italy
    • 7.3.8 Russia
    • 7.3.9 Rest Of Europe
  • 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.4.1 By Type
    • 7.4.2 By Route Of Administration
    • 7.4.3 By End User
    • 7.4.4 India
    • 7.4.5 Japan
    • 7.4.6 South Korea
    • 7.4.7 Australia
    • 7.4.8 South East Asia
    • 7.4.9 Rest Of Asia Pacific
  • 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.5.1 By Type
    • 7.5.2 By Route Of Administration
    • 7.5.3 By End User
    • 7.5.4 Brazil
    • 7.5.5 Argentina
    • 7.5.6 Peru
    • 7.5.7 Chile
    • 7.5.8 Rest of Latin America
  • 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.6.1 By Type
    • 7.6.2 By Route Of Administration
    • 7.6.3 By End User
    • 7.6.4 Saudi Arabia
    • 7.6.5 UAE
    • 7.6.6 Israel
    • 7.6.7 South Africa
    • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

  • 8.1. Recent Developments
  • 8.2. Company Categorization
  • 8.3. Supply Chain & Channel Partners (based on availability)
  • 8.4. Market Share & Positioning Analysis (based on availability)
  • 8.5. Vendor Landscape (based on availability)
  • 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL GASTRIC CANCER DRUGS INDUSTRY

  • 9.1. Top Companies Market Share Analysis
  • 9.2. Company Profiles
    • 9.2.1 Arlak Biotech
    • 9.2.2 Astellas Pharma Inc
    • 9.2.3 AstraZeneca Plc
    • 9.2.4 BeiGene
    • 9.2.5 Biocad
    • 9.2.6 Biocon
    • 9.2.7 Bristol-Myers Squibb
    • 9.2.8 CARsgen Therapeutics
    • 9.2.9 Celon Pharma
    • 9.2.10 Celltrion Inc
    • 9.2.11 CStone Pharma
    • 9.2.12 Daiichi Sankyo
    • 9.2.13 Eli Lilly And Company
    • 9.2.14 Eurofarma Laboratorios S.A
    • 9.2.15 F. Hoffmann-La Roche
    • 9.2.16 Gilead Sciences
    • 9.2.17 GlaxoSmithKline Plc
    • 9.2.18 Jiangsu HengRui Medicine
    • 9.2.19 Johnson & Johnson
    • 9.2.20 JW Therapeutics
    • 9.2.21 Merck & Co. Inc
    • 9.2.22 Mylan Laboratories
    • 9.2.23 Novartis Oncology
    • 9.2.24 PV Pharma Healthcare
    • 9.2.25 Pfizer Inc
    • 9.2.26 Sandoz AG (Novartis)
    • 9.2.27 Sanofi
    • 9.2.28 Takeda Pharmaceuticals
    • 9.2.29 Teva Pharmaceutical Industries Ltd
    • 9.2.30 TUTEUR / Pierre Fabre Group